Spending on Direct-to-Consumer Advertising Takes a Nosedive
This article reviews data that supports one cause for the decrease in DTC spending not often mentioned: the shift to developing drugs for small populations of patients (so-called
Reigning in the “Wild West” of Mobile Health Apps
As with Web sites in the early days, it is difficult today for users of mobile health apps to be assured that the apps are reliable, accurate, based on valid information, and adequately safeguard users' information. In many ways, we are living through another digital
Reigning in the “Wild West” of Mobile Health Apps
As with Web sites in the early days, it is difficult today for users of mobile health apps to be assured that the apps are reliable, accurate, based on valid information, and adequately safeguard users' information. In many ways, we are living through another digital
Self-Regulation as a Collective Blocking Strategy
Has the drug industry systematically violated PhRMA's DTC Principles? Is pharma self-regulation a deception meant to deflect criticism and block new FDA regulations? The answer is
Will Ethics Revive (Exhume?) the Drug Industry’s Reputation?
Jennifer Miller, a fellow at the Edmund J Safra Center for Ethics at Harvard University and president of Bioethics International, a non-profit that advises educational programs on ethical issues on medicine and healthcare, is trying to develop the industry equivalent of a 'Good Housekeeping Seal of Approval.' This article summarizes her ideas and presents opinions of several naysayers.
Pharma Marketing News Vol. 12, No. 2: 20 February 2013
Welcome to Volume 12, Issue #2 (20 February 2013) of Pharma Marketing News.
Pharma Marketing News Vol. 12, No. 1: 31 January 2013
Welcome to Volume 12, Issue #1 (31 Januray 2013) of Pharma Marketing News.
Pharma Marketing News Vol. 12, No. 1: 31 January 2013
Welcome to Volume 12, Issue #1 (31 Januray 2013) of Pharma Marketing News.
Pharmaguy’s Pharma Predictions
To usher in the New Year, it's traditional for pundits like Pharmaguy (aka John Mack, Publisher of Pharma Marketing News) to go out on a limb and make a few pharma industry predictions for the year.
Bad, Devalued, Distrusted & Defensive Pharma
This article, however, tells the Tale of Two Books: Bad Pharma, a 430-page book by Ben Goldacre, a British physician, whose previous book, Bad Science, was a best seller in the 'non-fiction' realm and the much smaller 123-page book Devalued and Distrusted by John L. LaMattina, former president of research and develop at Pfizer.
